GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xlife Sciences AG (XSWX:XLS) » Definitions » Capex-to-Operating-Cash-Flow

Xlife Sciences AG (XSWX:XLS) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Xlife Sciences AG Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Xlife Sciences AG's Capital Expenditure for the six months ended in Dec. 2023 was CHF0.00 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was CHF2.91 Mil.

Hence, Xlife Sciences AG's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.00.


Xlife Sciences AG Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Xlife Sciences AG's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xlife Sciences AG Capex-to-Operating-Cash-Flow Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - 0.24

Xlife Sciences AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xlife Sciences AG's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Xlife Sciences AG's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xlife Sciences AG's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Capex-to-Operating-Cash-Flow falls into.



Xlife Sciences AG Capex-to-Operating-Cash-Flow Calculation

Xlife Sciences AG's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.041) / 0.172
=0.24

Xlife Sciences AG's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 2.911
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xlife Sciences AG  (XSWX:XLS) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Xlife Sciences AG Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Xlife Sciences AG's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Xlife Sciences AG (XSWX:XLS) Business Description

Traded in Other Exchanges
Address
Talacker 35, Zürich, CHE, 8001
Xlife Sciences AG is a Swiss company with a focus on performance technologies in life sciences. The company allows its investors a very early and direct Entry into the further development of innovative and future-oriented technologies.

Xlife Sciences AG (XSWX:XLS) Headlines

No Headlines